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19F NMR In Vivo Spectroscopy Reﬂects the Effectiveness
of Perfusion-Enhancing Vascular Modiﬁers for Improving
Gemcitabine Chemotherapy
Greg O. Cron,1 Nelson Beghein,1 Re´ginald Ansiaux,1 Philippe Martinive,2
Olivier Feron,2 and Bernard Gallez1*
Nuclear magnetic resonance spectroscopy of ﬂuorine-19 (19F
NMR) has proven useful for evaluating kinetics of ﬂuorinated
chemotherapy drugs in tumors in vivo. This work investigated
how three perfusion-enhancing vascular modiﬁers (BQ123, tha-
lidomide, and Botulinum neurotoxin type A [BoNT-A]) would
affect the chemotherapeutic efﬁcacy of gemcitabine, a ﬂuori-
nated drug widely used in human cancer treatment. Murine
tumor growth experiments demonstrated that only BoNT-A
showed a strong trend to enhance tumor growth inhibition by
gemcitabine (1.7 days growth delay, P  0.052, Student t-test).
In accord with these results, 19F NMR experiments showed that
only BoNT-A increased signiﬁcantly the uptake of gemcitabine
in tumors (50% increase, P  0.0008, Student t-test). Further
experiments on gemcitabine kinetics (NMR vs time) and distri-
bution (19F MRI) conﬁrmed the uptake-enhancing properties of
BoNT-A. The results of this study demonstrate that 19F NMR can
monitor modulation of the pharmacokinetics of ﬂuorinated che-
motherapy drugs in tumors. The results also show that 19F NMR
data can give a strong indication of the effectiveness of perfu-
sion-enhancing vascular modiﬁers for improving gemcitabine
chemotherapy in murine tumors. 19F NMR is a promising tool for
preclinical evaluation of such vascular modiﬁers and may ulti-
mately be used in the clinic to monitor how these modiﬁers
affect chemotherapy. Magn Reson Med 59:19–27, 2008.
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Nuclear magnetic resonance spectroscopy of ﬂuorine-19
nuclei (19F NMR) has proven to be a useful tool for inves-
tigating noninvasively the pharmacokinetics of ﬂuorinated
chemotherapy drugs in tumors in vivo (1–4). 19F NMR
experiments performed on humans (5–7) and animals (8–
23) have found signiﬁcant correlations between cancer
treatment success, normal tissue toxicity, the presence or
absence of externally administered biological modiﬁers
(e.g., carbogen), and the uptake and elimination of ﬂuori-
nated chemotherapy drugs in tumors and normal tissues.
Until now, most such 19F NMR studies have focused on
the chemotherapy drug 5-ﬂuorouracil. Only a small num-
ber of studies have dealt with the newer ﬂuorinated che-
motherapy drug gemcitabine (21,22). Moreover, to our
knowledge, no 19F NMR study has been performed using a
biological modiﬁer that acts directly on tumor vasculature
to enhance the perfusion (delivery) of the chemotherapy
drug. In the context of cancer treatment, this approach is
being pursued actively in preclinical models (24) and in
the clinic (25) to enhance the delivery of chemotherapeu-
tic agents and increase the efﬁcacy of the treatment. In our
laboratory, we have been experimenting with three such
perfusion-enhancing vascular modiﬁers (BQ123, thalido-
mide, and Botulinum neurotoxin type A [BoNT-A]), with
the goal of increasing tumor perfusion transiently to boost
the effectiveness of radiotherapy and chemotherapy (26–
30). BQ123 is an endothelin receptor antagonist that in-
duces tumor vessel dilation by blocking the effect of en-
dothelin-1 (ET-1), a very active vasoconstrictor released by
tumor cells (26). Thalidomide, an antiangiogenic agent,
has recently been shown to increase tumor blood ﬂow
transiently by means of a phenomenon referred to as “nor-
malization” of the tumor vasculature (pruning away of less
functional vessels) (27–29). BoNT-A has been demon-
strated to open up tumor vasculature (i.e., open previously
constricted or closed vessels) by decreasing vascular tone
(30). These three compounds are possible candidates for
clinical use in combination with cytotoxic therapies.
Agents that inhibit endothelin-1 receptors have already
been used in clinical trials for prostate cancer (31,32).
Thalidomide is one of the most studied antiangiogenic
agents in clinical trials, including usage in combination
with chemotherapeutic agents (33). Finally, BoNT-A has
been widely used in the clinic with a long-term estab-
lished absence of toxicity (absence of systemic effects)
when used appropriately (34). Thus, it is certainly valid to
envision clinical trials with local administration of
BoNT-A in easily accessible tumors.
The original purpose of this work was to test how those
three vascular modiﬁers would affect gemcitabine chemo-
therapy. After some murine tumor growth experiments
(described below), we found that only BoNT-A enhanced
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signiﬁcantly gemcitabine chemotherapy. To gain some un-
derstanding of these results, we then used 19F NMR in vivo
to measure the effect of the modiﬁers on the uptake of
gemcitabine in the tumors. For the modiﬁer that had the
most spectacular effect (BoNT-A), we performed further
19F NMR experiments to study gemcitabine elimination
and distribution (the latter through 19F MR imaging).
MATERIALS AND METHODS
All experiments were performed according to national an-
imal care regulations. Intramuscular hepatomas were im-
planted in the gastrocnemius muscle of the right hind limb
of male NMRI (Naval Marine Research Institute) mice
(30–35 g, Janvier) (35). These tumors are hypoxic (oxy-
gen partial pressure  5 mmHg) and poorly perfused (typ-
ically less than half of tumor volume with measurable
perfusion), thus mimicking cancers in the clinic that are
highly resistant to radiation therapy and chemotherapy.
Five different groups of these tumors were grown (on
different dates), for a total of 124 tumors (Table 1). Tumor
diameters (anterior–posterior axis) were measured manu-
ally using calipers (26–28,30). To maximize consistency,
the same experimenter (G.O.C.) performed all diameter
measurements. Treatments for a given tumor were begun
on “day 0,” when the tumor had reached a diameter of
6 mm. The diameter of the tumors on day 2 was 8.0 
0.1 mm (numbers given as mean  SEM unless otherwise
stated). Based on T2-weighted imaging of the mice used for
NMR/MRI (groups 2 through 5 in Table 1), the three-
dimensional volume of the tumors on day 2 was 0.85 
0.03 cm3. Previously acquired (unpublished) MRI data in
our laboratory relating the volume of these tumors to man-
ually measured anterior–posterior diameter indicate that a
diameter of 6 mm corresponds to a tumor volume of ap-
proximately 0.55 cm3 (15 mm corresponds to2.7 cm3). In
Table 1, “DMSO” refers to an intraperitoneal (i.p.) injec-
tion of 100 L dimethyl sulfoxide (DMSO); “BQ123” refers
to an i.p. injection of 1 mg/kg BQ123 (Sigma, Bornem,
Belgium); “thal.” refers to an i.p. injection of 200 mg/kg
racemic thalidomide (Sigma-Aldrich, Bornem, Belgium)
dissolved in a volume of 100 L of DMSO; “BoNT-A”
refers to an intratumoral injection of Botulinum neuro-
toxin type A (BoNT-A; Botox, Allergan, Antwerp, Bel-
gium; 2 injections of 20 l at different sites, corresponding
to a total dose of 29 U kg1); and “gemci.” refers to an i.p.
injection of gemcitabine (Gemzar, Eli Lilly) at 5 mg/kg for
group 1, 800 mg/kg for groups 2–4, and 1600 mg/kg for
group 5. “BQ123gemci.” indicates that BQ123 was ad-
ministered at the same time as gemcitabine (separation 
2 min). A dash “-” indicates no treatment or a sham treat-
ment with saline solution. It should be noted that, when a
treatment was performed on a mouse, the treatment was
only administered once on the given day. The scheduling,
doses, and routes of administration of BQ123, thalido-
mide, and BoNT-A followed those of previously published
work and have been shown to increase tumor perfusion
signiﬁcantly (26–28,30).
For NMR and MR imaging experiments, animals were
anesthetized by inhalation of isoﬂurane mixed with air in
a continuous ﬂow (1.8 l/h), delivered by a nose cone.
Anesthesia was initiated with 3% isoﬂurane, then stabi-
lized at 1.5% isoﬂurane for 10 min before any manipu-
lation. Animals were maintained at 37°C in the MRI scan-
ner by ﬂushing warm air inside the bore.
Tumor Growth Experiments
A group of 70 tumors was prepared for growth experi-
ments (group 1 in Table 1). This group was subdivided
into eight subgroups of tumors, each subgroup receiving a
different treatment regimen shown by the table. The gem-
citabine dose of 5 mg/kg used for this group was chosen
after performing separate tumor growth experiments (data
not shown) to investigate the efﬁcacy of different doses of
gemcitabine varying from 0 to 100 mg/kg. Those experi-
ments showed that 5 mg/kg was below the efﬁcacy thresh-
old for this product, which ensured that any improve-
ments in efﬁcacy conferred by the biological modiﬁers
(BQ123, thalidomide, BoNT-A) would be reﬂected in the
growth curves. After treatments were performed on days
0–2, each tumor was allowed to grow until it reached a
diameter of 15 mm (volume 2.7 cm3), at which point the
mouse was killed. The time to grow from 8 mm (volume
0.85 cm3) (on day 2) to 15 mm (volume 2.7 cm3) was
recorded for each tumor. Differences in this growth time
between the different subgroups were assessed by means
of the Student t-test.
19F and 1H NMR Spectroscopy of Gemcitabine
Implementation of Spectroscopy and Phantom Validation
MR imaging and spectroscopy experiments were performed
with a Bruker Biospec 4.7T MRI scanner (Karlsruhe, Ger-
Table 1
Tumor Groups and Corresponding Treatments
Tumor growth experiments (n  70 total)
n day 0 day 1 day 2
group 1
9 – – –
7 DMSO DMSO –
9 thal. thal. –
10 BoNT-A – –
10 – – gemci.
5 – – BQ123  gemci.
11 thal. thal. gemci.
9 BoNT-A – gemci.
Initial uptake experiments (n  45 total)
n day0 day 1 day 2
group 2
9 – – gemci.
9 – – BQ123  gemci.
group 3
5 DMSO DMSO gemci.
6 thal. thal. gemci.
group 4
8 – – gemci.
8 BoNT-A – gemci.
Kinetics experiments (n  6 total)
n day 0 day 1 day 2
subset of group
4
3 – – gemci.
3 BoNT-A – gemci.
19F imaging experiments (n  9 total)
n day 0 day 1 day 2
group 5
4 – – gemci.
5 BoNT-A – gemci.
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many) and a 25-mmdiameter surface coil that could be tuned
separately to either 1H (200.1 MHz) or 19F (188.3 MHz). Pre-
liminary experience showed that the tumor 19F signal of
gemcitabine (administered i.p. to the mouse) was very small
(gemcitabine spectrum height divided by standard deviation
of noise was less than 5 for a gemcitabine dose of 100 mg/kg,
150 averages, repetition time  6 s). Thus, every possible
effort was made to maximize the 19F signal-to-noise ratio
(SNR). NMR spectroscopy was performed in a nonlocalized
manner (simple excite–acquire pulse sequence) to sample
the earliest possible time points of the free induction decay
(FID) and thereby increase spectra SNR. For mouse tumor
experiments, the surface coil was placed directly on the
tumor in such a way as to maximize the NMR signal received
from the tumor and minimize the signal from the upper leg
and paw. The tail and non–tumor-bearing left hind limbwere
positioned completely outside the sensitive volume of the
coil. A small, sealed glass capillary tube containing a small
sample of hexaﬂuorobenzene was permanently afﬁxed to the
underside of the coil. This procedure provided a consistent
19F signal easily distinguishable from gemcitabine (51 ppm
downﬁeld from gemcitabine) which was used for quality
assurance purposes (more details given at the end of this
section). As has been the case in previous work, the gemcit-
abine parent compound and metabolites were not distin-
guishable in the 19F spectra (21,22). Thus, gemcitabine was
treated as a single peak. 1H and 19F spectroscopy were per-
formed with the following parameters: excitation angle 
90°, spectral width  25 kHz, acquisition size  8k, repeti-
tion time  6 s (to ensure complete relaxation). For 1H spec-
troscopy, an 80-s-long block radio frequency (RF) excitation
pulse was used, whereas for 19F spectroscopy a 20-s-long
block pulse was used. Four averages were acquired for 1H
spectroscopy, whereas 150 averages were acquired for 19F
spectroscopy (total 19F acquisition time  15 min). The fre-
quency of the RF excitation pulse was centered directly on
thewater peak for 1H spectroscopy and7 ppmdownﬁeld of
the gemcitabine peak for 19F spectroscopy. FIDs were Fourier
transformed (exponential line broadening 25 Hz for 19F spec-
tra), phased, and baseline corrected. The real part of each
spectrum was integrated over the water peak for 1H spectros-
copy (integration width 20 ppm) and over the gemcitabine
peak for 19F spectroscopy (integrationwidth 12 ppm). Each
integral was divided by the receiver gain number used for
that acquisition. (The receiver gain for 19F spectroscopy was
always set to the same value, which was the maximum pos-
sible for the scanner.) A relativemeasure of the concentration
of gemcitabine measured by spectroscopy ([gem]rel) was then
obtained by dividing the gemcitabine integral by the water
integral.
Ten aqueous 1-ml plastic centrifuge tubes were pre-
pared with known concentrations of gemcitabine (range,
0–3 mM). These phantoms were used to test the reproduc-
ibility and linearity of [gem]rel as a function of gemcitabine
concentration. [gem]rel measurements with these phan-
toms were found to be linear with gemcitabine concentra-
tion (R  0.99) with a slope of 0.135 mM1. [gem]rel mea-
surements were henceforth multiplied by the inverse of
that slope, 7.41 mM, so that the numerical values of
[gem]rel would be approximately equal to the absolute con-
centrations of gemcitabine in mM. The equality between
[gem]rel and absolute concentration is only approximate,
because it assumes uniform distribution of gemcitabine,
homogeneous unit density of tissue, and no NMR-invisible
1H or 19F nuclei. [gem]rel measurements were found to be
reproducible to within 10% (0.16 mM), even when the
phantoms were completely removed from the scanner and
put back in with different geometrical orientations (neces-
sitating new shimming). For repeat measurements on the
same phantom (not removed from the scanner), the repro-
ducibility improved to  7% (0.11 mM).
For the in vivo 19F spectroscopy data, the integral of the
real part of the spectrum peak corresponding to the
hexaﬂuorobenzene reference tube (integration width 
18 ppm) was very stable from experiment to experiment,
varying by less than 7.5% of the mean for all studies
(standard deviation 3.7% of the mean). The positions (in
frequency) of the gemcitabine and hexaﬂuorobenzene
peaks were very stable as well (7.3  0.2 ppm for gem-
citabine, 43.5  0.6 ppm for hexaﬂuorobenzene,
mean  standard deviation, transmitter frequency 
188.2805 MHz). Thus, from a quality assurance viewpoint,
we considered that all our spectroscopy data were valid.
Initial Uptake in Tumors In Vivo
Three separate groups of tumors were prepared for NMR
experiments investigating the initial uptake of gemcitabine
in tumors (groups 2, 3, and 4 in Table 1). Each of these
groups was divided into a control subgroup (gemcitabine
only) and a treatment subgroup (gemcitabine  modiﬁer).
On day 2, gemcitabine (800 mg/kg) was injected i.p. into
the awake mouse in a fume hood facility approved for the
handling of chemotherapeutic agents. The dose of
800 mg/kg provided gemcitabine concentrations in the
tumor of 1–2 mM. This dose was chosen to ensure ade-
quate SNR and reproducibility for 19F spectroscopy. Pre-
liminary in vivo 19F spectroscopy tumor experiments with
gemcitabine doses of 100, 200, 400, and 800 mg/kg had
given SNRs (gemcitabine spectrum height divided by stan-
dard deviation of baseline noise) of approximately 4, 6, 13,
and 25, respectively (same 15-min acquisition described
above). Our technical goal was an SNR of at least 20 for a
15-min acquisition (repetition time  6 s), leading to our
choice of the 800 mg/kg dose. This dose is within the range
of single-dose chemotherapy experiments which have
been performed safely by other investigators (i.e., no acute
[hours] toxicity) (36).
After gemcitabine administration, the mouse (under
isoﬂurane anesthesia) was transported to the MRI facility
and installed in the MRI scanner. The surface coil was
initially set to 1H mode for shimming, preliminary imaging
(to check positioning), and 1H spectroscopy. Immediately
afterward, the coil was set to 19F mode and one spectros-
copy acquisition was begun. This acquisition commenced
37.5 min after the i.p. injection of gemcitabine and ﬁn-
ished 52.5 min after the injection (15-min acquisition).
Thus, the mean acquisition time post-i.p. was considered
to be 45 min ( the mean of 37.5 and 52.5 min). After the
end of the 19F acquisition, the coil was switched back to 1H
mode for multislice proton-density and T2-weighted imag-
ing of the tumor. For proton density-weighted imaging, a
gradient echo pulse sequence was used with ﬁeld of view
(FOV)  40 mm, matrix  64 	 64, 20 transverse (axial)
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slices, slice thickness  2 mm, repetition time  5 s, echo
time  4.5 ms, and ﬂip angle  90°. For T2-weighted
imaging, a fast spin echo pulse sequence was used with
FOV  40 mm, matrix  128 	 128, 20 transverse (axial)
slices, slice thickness  2 mm, repetition time  4 s, and
effective echo time  50 ms.
For each tumor, the 1H and 19F spectroscopy data were
used to compute the value of [gem]rel 45 min post-i.p.
injection of gemcitabine. For each tumor group (i.e.,
groups 2, 3, and 4 in Table 1), all [gem]rel values were
normalized to the average value found for the control
subgroup. This was done to facilitate comparisons be-
tween groups. For each tumor group, [gem]rel values for the
control subgroup were compared with values for the treat-
ment subgroup by means of the Student t-test.
Nonlocalized spectroscopy measurements gather NMR
signals not only from the tumor, but also from adjacent
muscle, fat, skin, and any other structure that is within the
sensitive volume of the surface coil. The proton-density
and T2-weighted images were used to estimate the percent-
age of total NMR signal produced by the tumor alone, to
rule out any biases in the data that could be caused by
variations in tissue composition. Regions of interest (ROIs)
were drawn around the tumor on the T2-weighted images.
These ROIs were then used to compute the percentage of
total MRI signal in the proton-density–weighted images
contributed by the tumor.
For ﬁve mice in each subgroup of group 4 (BoNT-A
experiments), 1 ml of blood was withdrawn by means of
cardiac puncture at the end of the experiment (60 min
post-i.p. injection of gemcitabine). The blood was placed
in a plastic heparinized centrifuge tube, and a [gem]rel
measurement was performed in the scanner to obtain an
estimate of the concentration of gemcitabine in the blood.
This procedure was to verify that any differences in tumor
[gem]rel between the control and treatment subgroups were
not due simply to differences in gemcitabine blood con-
centration.
Kinetics in Tumors In Vivo (BoNT-A Experiments)
Six tumors (three controls, three treated with BoNT-A)
from group 4 were used to investigate [gem]rel as a function
of time. The protocol and analysis were similar to the
initial uptake experiments, except that 16 sequential 19F
acquisitions were performed instead of 1. Additionally, a
maximum possible effort was made to perform the initial
steps of the protocol quickly (transportation of the mouse,
installation in the scanner, and so on), which allowed the
mean acquisition time post-i.p. of the ﬁrst 19F spectrum to
be 30 min (start of acquisition  22.5 min, end of acqui-
sition  37.5 min) instead of the usual mean acquisition
time of 45 min. For each tumor, the 1H and 19F spectros-
copy data were used to compute the value of [gem]rel as a
function of time post-i.p. injection of gemcitabine. Here,
[gem]rel values were not normalized to the control sub-
group. These [gem]rel vs time data were then used to com-
pute the area under the curve (AUC, for all time points)
and the slope of the elimination phase of the curve (linear
regression performed on time points 
 120 min).
19F MR Imaging of Gemcitabine in Tumors In Vivo
19F MR imaging of gemcitabine was performed on a group
of nine tumors (four control, ﬁve treated with BoNT-A,
group 5 in Table 1). The protocol was similar to that used
for the spectroscopy experiments. The gemcitabine dose
used for 19F imaging was 1600 mg/kg instead of 800 mg/kg.
This doubling of the dose used for spectroscopy was
deemed necessary after preliminary experiments showed
that the 19F image SNR would not be adequate with
800 mg/kg. To our knowledge, 1600 mg/kg administered to
a mouse is greater than any single dose that has ever been
used by other investigators. Thus, to ensure a lack of acute
(hours) toxicity, a separate group of ﬁve mice (not in-
cluded in Table 1) was injected with that dose and ob-
served for 24 hr. No deaths, weight loss, or adverse behav-
ioral effects were observed for that time period.
For the 19F imaging experiments, after the mice were
installed in the MRI scanner, the 1H mode of the surface
coil was used for shimming and preliminary imaging (to
check positioning). The coil was then switched to 19F
mode. One 19F spectrum was acquired to ﬁnd the precise
center frequency of the gemcitabine peak. Using this as the
center transmit frequency, a 19F gradient echo imaging
pulse sequence was then commenced. This pulse se-
quence acquired a single projection image (i.e., inﬁnite
slice thickness) in the coronal plane. Other parameters
were as follows: FOV  70 mm, matrix  32 	 32, repe-
tition time  6 s, echo time  2.1 ms, ﬂip angle  90°,
number of averages  16, total acquisition time  51 min.
A gaussian RF pulse shape with length 680 s was used for
excitation. This pulse had no signiﬁcant spectral power at
frequencies farther than5 kHz from the center frequency.
This ensured that the 19F signals from the isoﬂurane anes-
thetic (6.4 kHz upﬁeld of the gemcitabine peak) and the
hexaﬂuorobenzene sample (9.6 kHz downﬁeld) would
not contaminate the gemcitabine images. The time be-
tween the i.p. injection of gemcitabine and the midpoint of
the 19F image acquisition was 62 min.
After 19F imaging, the coil was switched back to 1H
mode. A proton-density–weighted projection image was
acquired, whose pulse sequence was nearly identical to
the one used for 19F imaging (except 2 averages and center
frequency set to the water peak). Finally, a T2-weighted
projection image was acquired (FOV  70 mm, matrix 
128 	 128, repetition time  4 s, echo time  50 ms).
The pixel values of the 19F and proton density projection
images were divided by their respective receiver gain
numbers. (The receiver gain for 19F imaging was always set
to the same value, which was the maximum possible for
the scanner.) An ROI was drawn around the empty space
(air) surrounding the tumor mass in the 19F image to com-
pute the mean and standard deviation of the image noise.
Pixels whose 19F signal did not exceed the mean noise
level by at least 2 SDs were excluded from further analysis.
It should be noted that the image noise in empty space (air)
has a Rayleigh distribution with nonzero mean, which
may differ from the noise distribution of the object in the
image (37). Our simple calculations of the mean and stan-
dard deviation of the noise were not used for any analyses,
only for thresholding. Pixels whose proton density signal
was less than 10% of the maximum signal in the tumor
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mass were also excluded. An estimate of the [gem]rel dis-
tribution (i.e., a [gem]rel image) was then obtained by di-
viding the 19F image by the proton density image. The
[gem]rel values for all images were then normalized to the




The mice tolerated all treatments well, with no deaths and
minimal weight loss ( 5%; drugs administered as in
Table 1 group 1, then mice monitored daily with no further
treatments up to 12 days postgemcitabine). Tumors in
animals treated with gemcitabine grew more slowly than
those in animals which were not treated with gemcitabine
(8.1 0.3 days vs 5.8 0.3 days, n 35 vs 35, P 0.0001,
all subgroups combined, where “days” refers to the num-
ber of days required for the tumor to grow from 8 mm
[volume0.85 cm3] to 15 mm [volume2.7 cm3]). Among
animals not treated with gemcitabine, there was no signif-
icant difference in tumor growth observed between sub-
groups. Among animals treated with gemcitabine, the re-
sults of the different subgroups are shown in Figure 1.
There was no signiﬁcant difference in tumor growth be-
tween the control subgroup (gemcitabine only) and the
treatment (gemcitabine  modiﬁer) subgroups, with the
exception of BoNT-A. Tumors treated with gemcitabine
plus BoNT-A grew more slowly than tumors treated with
gemcitabine only (9.4  0.6 days vs 7.7  0.5 days, n  9
vs 10, P  0.052).
19F and 1H NMR Spectroscopy of Gemcitabine
Initial Uptake in Tumors In Vivo
Figure 2 shows example in vivo 19F NMR spectra. Figure 3
shows the results of the 19F spectroscopy initial uptake
experiments. Similar to the tumor growth experiments,
there was no signiﬁcant difference in gemcitabine uptake
between the control subgroups (gemcitabine only) and the
treatment (gemcitabine  modiﬁer) subgroups, with the
exception of BoNT-A. Tumors treated with BoNT-A had a
higher uptake of gemcitabine than controls (50% more,
P  0.0008). Additionally, there was no signiﬁcant differ-
ence in [gem]rel between blood samples withdrawn from
BoNT-A–treated mice and blood samples withdrawn from
controls (2.9  0.4 mM vs 3.2  0.3 mM, where relative
concentrations of gemcitabine were converted to estimates
of absolute concentration by means of the scaling factor
described in the Materials and Methods section). Finally,
the estimate of the fraction of total NMR signal attributable
to the tumor did not vary signiﬁcantly between subgroups
(MRI signal intensity from tumor volume divided by total
MRI signal intensity  0.63 on average).
Kinetics in Tumors In Vivo (BoNT-A Experiments)
Figure 4 shows the results of the gemcitabine kinetics
experiments involving BoNT-A. For this ﬁgure, relative
concentrations of gemcitabine were converted to absolute
ones (mM) by means of the scaling factor described in the
Materials and Methods section. The approximate symbol
() has been placed in front of the mM symbol, however,
because the conversion makes unveriﬁed assumptions of
uniform distribution of gemcitabine, homogeneous unit
density of tissue, and no NMR-invisible 1H or 19F nuclei.
Tumors treated with BoNT-A received more gemcitabine
over time than controls: The average AUC for the former
subgroup was 40% higher than for the latter (356  14 vs
252  22, units of mM min, P  0.02, Student t-test). No
statistically signiﬁcant difference in elimination rate was
observed between the two subgroups (0.0025 
0.0005 mM/min for the control group vs 0.0038 
0.0011 mM/min for the BoNT-A group).
19F MRI of Gemcitabine in Tumors In Vivo
Figure 5 shows example images from the 19F imaging ex-
periments. Pooling all [gem]rel values for all pixels of the
treatment group (141 total pixels for the 5 animals) and
comparing them with those of the control group (120 total
pixels for the 4 animals), the [gem]rel values for the treat-
ment group were signiﬁcantly higher than those of the
control group (1.21  0.07 vs 1.00  0.05, P  0.015,
Student t-test). Taking the average [gem]rel value for each
image and comparing the two groups (5 [gem]rel values for
the treatment group vs 4 [gem]rel values for the control
group), the treatment group had higher [gem]rel values but
the difference was not quite statistically signiﬁcant (1.22
0.10 vs 1.00  0.05, P  0.1).
DISCUSSION
The results of the initial uptake experiments closely
matched those of the tumor growth experiments (compare
FIG. 1. Time for murine intramuscular hepatomas to grow to 15 mm
diameter (volume 2.7 cm3; starting point  8.0  0.1 mm, volume
0.85 cm3). Thirty-ﬁve tumors (grown using the same cell suspen-
sion and same batch of mice) were divided into four experimental
subgroups. The control subgroup (n  10) was treated with gem-
citabine 5 mg/kg alone. The other three subgroups were treated
with gemcitabine plus a modiﬁer (BQ123, n  5; thalidomide, n 
11; and BoNT-A, n 9). The results of the control group (circles) are
shown next to the results of each modiﬁer group for comparison.
Vertical brackets to the right of each group show mean  SEM for
that group. N.S.  no signiﬁcant difference between groups. * 
signiﬁcant difference between groups, student t-test, P  0.052.
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Figs. 1 and 3). Among the three modiﬁers, only BoNT-A
showed a strong trend to enhance tumor growth inhibition
by gemcitabine (P  0.052) and gemcitabine uptake (P 
0.0008). Considering the results qualitatively, there ap-
pears to be the same trend in both ﬁgures whereby BQ123
is the least effective modiﬁer, followed by thalidomide,
followed by the most effective modiﬁer BoNT-A. The re-
sults of the kinetics experiments in Figure 4 conﬁrm that
BoNT-A does indeed increase signiﬁcantly the exposure of
the tumor to gemcitabine (greater AUC, P  0.02). Thus, it
appears that the differences in gemcitabine chemosensiti-
zation for the three modiﬁers can be explained by corre-
sponding differences in gemcitabine tumor uptake en-
hancement that they confer.
This study supports the assumption that 19F NMR ex-
periments can provide a reliable description of the phar-
macokinetics of ﬂuorinated chemotherapy drugs in tu-
mors. In the context of the current work, these results
suggest that 19F NMR data can give a strong indication of
the effectiveness of perfusion-enhancing vascular modiﬁ-
ers for improving gemcitabine chemotherapy in murine
tumors.
At this time, it is not fully understood why the three
modiﬁers affect gemcitabine uptake in tumors differently
(and thus, chemosensitize differently). The data presented
in this work are the ﬁrst systematic, direct, comparison of
the perfusion-enhancing and chemosensitization abilities
of the three modiﬁers. Considering previously published
data, however, it is possible to make some approximate
comparisons of the three modiﬁers based upon laser Dopp-
ler imaging and Patent Blue staining (26–28,30). In the
same tumor model, BQ123 and thalidomide were each
found to cause an increase in laser Doppler-measured tu-
mor blood ﬂow of 25% (relative to controls) (26,27).
Thalidomide was found to increase the amount of tumor
exposed to Patent Blue staining by 70% (relative to con-
trols) (27), whereas BoNT-A was found to increase the
amount of tumor exposed to Patent Blue staining by
FIG. 2. Example in vivo 19F NMR spectra for intramuscular hepatomas as a function of time after i.p. injection of gemcitabine 800 mg/kg.
Identical scales have been used for all spectra. Each spectrum shows isoﬂurane peaks ( 45 ppm), the gemcitabine peak ( 7 ppm),
and the hexaﬂuorobenzene reference peak ( 45 ppm). a: Spectra for a control tumor (no vascular modiﬁers administered). b: Spectra
for a tumor pretreated with BoNT-A.
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105% (30). This comparison of the three modiﬁers, al-
though not rigorous, is consistent with the current study,
where it was found that BoNT-A provided superior perfu-
sion enhancement compared with the other two modiﬁers.
Of note, our study does not exclude that thalidomide and
BQ123 administered according to a different scheme (e.g.,
repeated exposure or higher dosage) might lead to a sig-
niﬁcant gain in chemotherapy uptake.
The dose of gemcitabine that was used for the in vivo 19F
spectroscopy tumor experiments (800 mg/kg) is higher
than that used in similar work by previous investigators
(e.g., 160 and 500 mg/kg for references 21 and 22). How-
ever, these previous studies used tumor models different
from ours, did not report spectra SNR, and did not report
estimates of absolute gemcitabine concentration in tumor,
making comparisons with our work difﬁcult. Relative to
our 19F spectroscopy acquisition parameters, the study
performed with 160 mg/kg used a smaller spectral width
(20 kHz), wider line broadening (40 Hz), longer acquisition
times (30 min), and a shorter repetition time (1.5 s, which
provides more FIDs and thus more averaging), all of which
boost SNR (21). We used a long repetition time (6 s) to
ensure complete spin-lattice relaxation of the 19F nuclei,
thus improving quantiﬁcation. It should also be noted that
the dose of 800 mg/kg used in our study is higher than that
used for clinical human chemotherapy (300–350 mg/kg
equivalent for a 25-g mouse). It is expected that these
clinical doses would still provide adequate SNR if 19F
NMR gemcitabine spectroscopy studies were performed
on humans, especially given the typically large size of
human tumors compared with murine tumors. We also
note that, although a dose of 800 mg/kg caused no acute
toxicity in our and other studies, we currently have no
data on how such a high dose may affect tumor perfusion
by means of either direct effects on tumor endothelium or
nonspeciﬁc effects (36).
FIG. 3. Relative concentration of gemcitabine in tumor mass 45 min
after i.p. injection of gemcitabine 800 mg/kg, as measured by in vivo
NMR spectroscopy. Three different groups of murine intramuscular
hepatomas, each subdivided into a control and modiﬁer group,
were investigated: BQ123 (n  9 controls, 9 treated with modiﬁer);
thalidomide (n  5 controls, 6 modiﬁer); and BoNT-A (n  8 con-
trols, 8 modiﬁer). For each of the three groups, relative gemcitabine
concentrations (mM) were normalized to the mean value found for
the control group. Vertical brackets to the right of each group show
mean  SEM for that group. N.S.  no signiﬁcant difference be-
tween groups. ***  highly signiﬁcant difference between groups,
student t-test, P  0.0008.
FIG. 4. Kinetics of the relative concentration of gemcitabine in the
tumor mass after i.p. injection of gemcitabine 800 mg/kg, as mea-
sured by in vivo NMR spectroscopy. Six murine intramuscular hep-
atomas were subdivided into a control (n  3) and BoNT-A modiﬁer
(n  3) group. Data points (mean  SEM) were obtained by aver-
aging the concentrations from the three tumors of that group. The
units of the vertical axis are absolute gemcitabine concentrations in
millimolar (mM). For this ﬁgure, relative concentrations of gemcit-
abine were converted to absolute ones by means of the scaling
factor described in the Materials and Methods section. The approx-
imate symbol () has been placed in front of the mM symbol,
however, because the conversion makes unveriﬁed assumptions of
uniform distribution of gemcitabine, homogeneous unit density of
tissue, and no NMR-invisible 1H or 19F nuclei.
FIG. 5. Results of two murine intramuscular hepatoma imaging
experiments. All images are projections (single-slice, inﬁnite slice
thickness) in the coronal plane (FOV  7 cm, images cropped). Top
row: a control study. Bottom row: a BoNT-A modiﬁer study. Shown
are 128 	 128 T2-weighted 1H images (leftmost column), 32 	 32
proton density-weighted 1H images (second column), 32x32 19F
images (third column), and 32	 32 images of relative concentration
of gemcitabine (rightmost column). Color scale shows relative con-
centration of gemcitabine. (Relative concentrations of gemcitabine
have been normalized to the average value for the control group, to
facilitate comparisons.)
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For the NMR spectroscopy experiments involving the
initial uptake of gemcitabine, the relative concentration of
gemcitabine was measured essentially at a single time
point (45 min post-i.p.). From a pharmacokinetics view-
point, it is better to measure the entire time course (e.g.,
from 0 to 250 min) and compute the AUC to obtain a
measure of the exposure of the tumor to the drug. Com-
pared with a single time point, the AUC is less affected by
any potential animal-to-animal variations in the vascular
input function and tumor pharmacokinetic parameters
(e.g., tumor blood volume, capillary permeability, rates of
cellular uptake and metabolism). AUC experiments are
expensive, however, requiring large amounts of scanner
time per animal. The strategy that we have envisioned is
thus to use the single-time-point experiments as an initial
“screening” test of the effectiveness of the vascular modi-
ﬁers, followed up by AUC and 19F imaging experiments if
the results are promising. It should be kept in mind that,
according to pharmacokinetic theory, it is possible for the
results of single-time-point experiments to contradict
those of AUC experiments, depending upon when the
single time point is acquired. For the long-acting vascular
modiﬁers used in this study (constant or gradually increas-
ing effects with time constants ranging from hours to
days), we believe that such a scenario is unlikely to have
happened, especially considering the agreement with the
tumor growth experiments.
We note that safety regulations prohibited us from han-
dling chemotherapy drugs in the MRI laboratory, which
prevented us from injecting gemcitabine while the animals
were in the scanner (to obtain data starting at time 0).
Collecting data from time 0 would not have changed the
overall result of the BoNT-A AUC experiments (Fig. 4),
however. This is because the control data (open circles)
reached peak concentration at 90 min. Pharmacokinetic
theory would predict a smooth connection for the control
data (i.e., relatively straight line) between 0 and 30 min,
making it impossible for the AUC of the control data to
exceed that of the BoNT-A data (ﬁlled squares).
Until now, few studies have attempted to obtain 19F MR
images of the distribution of ﬂuorinated chemotherapy
drugs, and none of these have demonstrated sufﬁcient 19F
sensitivity to image individual tumors in any appreciable
detail (23). Figure 5 shows 19FMR images that we obtained of
gemcitabine in tumors in vivo (spatial resolution 2.2 mm).
To our knowledge, these are the most detailed such images
that have been published to date. There was a strong trend of
higher [gem]rel values in the group treated with BoNT-A (P
0.015 when all pixels are pooled into treatment vs control
groups), which is consistent with the spectroscopy experi-
ments. Moreover, we observed qualitatively a “ring” en-
hancement pattern (more gemcitabine in the periphery of the
tumor compared with the center, e.g., Fig. 5 BoNT-A) in at
least ﬁve of the nine tumors, which is consistent with tumor
perfusion patterns often found with Gadolinium-enhanced
MRI (38). Although these 19F MRI results are very encourag-
ing, the quality of the images still warrants improvement. It
may be possible to increase the SNR of the images, for exam-
ple, by acquiring the low-frequency components of the k-
space lines (containing the most important image informa-
tion) earlier in the free induction decay, thereby shortening
the effective echo time.
CONCLUSIONS
The results of this study support the assumption that 19F
NMR experiments can provide a reliable description of the
pharmacokinetics of ﬂuorinated chemotherapy drugs in
tumors. The results also show that 19F NMR data can give
a strong indication of the effectiveness of perfusion-en-
hancing vascular modiﬁers for improving gemcitabine
chemotherapy in murine tumors. 19F NMR is a promising
tool for preclinical evaluation of such vascular modiﬁers
and may ultimately be used in the clinic to monitor how
these modiﬁers affect chemotherapy.
ACKNOWLEDGMENT
The authors thank Dr. Arturo Cardenas-Blanco for helpful
discussions regarding statistical issues.
REFERENCES
1. van Laarhoven HW, Punt CJ, Kamm YJ, Heerschap A. Monitoring
ﬂuoropyrimidine metabolism in solid tumors with in vivo (19)F mag-
netic resonance spectroscopy. Crit Rev Oncol Hematol 2005;56:321–
343.
2. Yu JX, Kodibagkar VD, Cui W, Mason RP. 19F: a versatile reporter for
non-invasive physiology and pharmacology using magnetic resonance.
Curr Med Chem 2005;12:819–848.
3. Martino R, Malet-Martino M, Gilard V. Fluorine nuclear magnetic res-
onance, a privileged tool for metabolic studies of ﬂuoropyrimidine
drugs. Curr Drug Metab 2000;1:271–303.
4. Robinson SP, Barton SJ, McSheehy PM, Grifﬁths JR. Nuclear magnetic
resonance spectroscopy of cancer. Br J Radiol 1997;70:60–69.
5. van Laarhoven HW, Klomp DW, Kamm YJ, Punt CJ, Heerschap A. In
vivo monitoring of capecitabine metabolism in human liver by 19ﬂu-
orine magnetic resonance spectroscopy at 1.5 and 3 Tesla ﬁeld strength.
Cancer Res 2003;63:7609–7612.
6. Dzik-Jurasz AS, Collins DJ, Leach MO, Rowland IJ. Gallbladder local-
ization of (19)F MRS catabolite signals in patients receiving bolus and
protracted venous infusional 5-ﬂuorouracil. Magn Reson Med 2000;44:
516–520.
7. Wolf W, Presant CA, Waluch V. 19F-MRS studies of ﬂuorinated drugs
in humans. Adv Drug Deliv Rev 2000;41:55–74.
8. van Laarhoven HW, Gambarota G, Lok J, Lammens M, Kamm YL,
Wagener T, Punt CJ, van der Kogel AJ, Heerschap A. Carbogen breath-
ing differentially enhances blood plasma volume and 5-ﬂuorouracil
uptake in two murine colon tumor models with a distinct vascular
structure. Neoplasia 2006;8:477–487.
9. McSheehy PM, Port RE, Rodrigues LM, Robinson SP, Stubbs M, van der
Borns K, Peters GJ, Judson IR, Leach MO, Grifﬁths JR. Investigations in
vivo of the effects of carbogen breathing on 5-ﬂuorouracil pharmacoki-
netics and physiology of solid rodent tumours. Cancer Chemother
Pharmacol 2005;55:117–128.
10. Kamm YJ, Peters GJ, Hull WE, Punt CJ, Heerschap A. Correlation
between 5-ﬂuorouracil metabolism and treatment response in two vari-
ants of C26 murine colon carcinoma. Br J Cancer 2003;89:754–762.
11. Kamm YJ, Heerschap A, Wagener DJ. Effect of carbogen breathing on
the pharmacodynamics of 5-ﬂuorouracil in a murine colon carcinoma.
Eur J Cancer 2000;36:1180–1186.
12. Katzir I, Shani J, Wolf W, Chatterjee-Parti S, Berman E. Enhancement of
5-ﬂuorouracil anabolism by methotrexate and trimetrexate in two rat
solid tumor models, Walker 256 carcinosarcoma and Novikoff hepa-
toma, as evaluated by 19F-magnetic resonance spectroscopy. Cancer
Invest 2000;18:20–27.
13. Lemaire LP, McSheehy PM, Grifﬁths JR. Pre-treatment energy status of
primary rat tumours as the best predictor of response to 5-ﬂuorouracil
chemotherapy: a magnetic resonance spectroscopy study in vivo. Can-
cer Chemother Pharmacol 1998;42:201–209.
14. McSheehy PM, Robinson SP, Ojugo AS, Aboagye EO, Cannell MB,
Leach MO, Judson IR, Grifﬁths JR. Carbogen breathing increases 5-ﬂu-
orouracil uptake and cytotoxicity in hypoxic murine RIF-1 tumors: a
magnetic resonance study in vivo. Cancer Res 1998;58:1185–1194.
26 Cron et al.
15. McSheehy PM, Seymour MT, Ojugo AS, Rodrigues LM, Leach MO,
Judson IR, Grifﬁths JR. A pharmacokinetic and pharmacodynamic
study in vivo of human HT29 tumours using 19F and 31P magnetic
resonance spectroscopy. Eur J Cancer 1997;33:2418–2427.
16. Holland SK, Bergman AM, Zhao Y, Adams ER, Pizzorno G. 19F NMR
monitoring of in vivo tumor metabolism after biochemical modulation
of 5-ﬂuorouracil by the uridine phosphorylase inhibitor 5-benzylacyc-
louridine. Magn Reson Med 1997;38:907–916.
17. Blackstock AW, Kwock L, Branch C, Zeman EM, Tepper JE. Tumor
retention of 5-ﬂuorouracil following irradiation observed using 19F
nuclear magnetic resonance spectroscopy. Int J Radiat Oncol Biol Phys
1996;36:641–648.
18. Kamm VJ, Rietjens IM, Vervoort J, Heerschap A, Rosenbusch G, Hofs
HP, Wagener DJ. Effect of modulators on 5-ﬂuorouracil metabolite
patterns in murine colon carcinoma determined by in vitro 19F nuclear
magnetic resonance spectroscopy. Cancer Res 1994;54:4321–4326.
19. Shungu DC, Bhujwalla ZM, Li SJ, Rose LM, Wehrle JP, Glickson JD.
Determination of absolute phosphate metabolite concentrations in
RIF-1 tumors in vivo by 31P–1H-2H NMR spectroscopy using water as
an internal intensity reference. Magn Reson Med 1992;28:105–121.
20. McSheehy PM, Prior MJ, Grifﬁths JR. Prediction of 5-ﬂuorouracil cyto-
toxicity towards the Walker carcinosarcoma using peak integrals of
ﬂuoronucleotides measured by MRS in vivo. Br J Cancer 1989;60:303–
309.
21. Blackstock AW, Lightfoot H, Case LD, Tepper JE, Mukherji SK, Mitchell
BS, Swarts SG, Hess SM. Tumor uptake and elimination of 2,2-
diﬂuoro-2-deoxycytidine (gemcitabine) after deoxycytidine kinase
gene transfer: correlation with in vivo tumor response. Clin Cancer Res
2001;7:3263–3268.
22. Kristjansen PE, Quistorff B, Spang-Thomsen M, Hansen HH. Intratu-
moral pharmacokinetic analysis by 19F-magnetic resonance spectros-
copy and cytostatic in vivo activity of gemcitabine (dFdC) in two small
cell lung cancer xenografts. Ann Oncol 1993;4:157–160.
23. Brix G, Bellemann ME, Haberkorn U, Gerlach L, Bachert P, Lorenz WJ.
Mapping the biodistribution and catabolism of 5-ﬂuorouracil in tumor-
bearing rats by chemical-shift selective 19F MR imaging. Magn Reson
Med 1995;34:302–307.
24. Brunstein F, Eggermont AMM, Aan de Wiel-Ambagtsheer G, Van Tiel
ST, Rens J, Ten Hagen TLM. Synergistic antitumor effects of histamine
plus melphalan in isolated hepatic perfusion for liver metastases. Ann
Surg Oncol 2007;14:795–801.
25. Gupta N, Saleem A, Kotz B, Osman S, Aboagye EO, Phillips R, Vernon
C, Wasan H, Jones T, Hoskin PJ, Price PM. Carbogen and nicotinamide
increase blood ﬂow and 5-ﬂuorouracil delivery but not 5-ﬂuorouracil
retention in colorectal cancer metastases. Clin Cancer Res 2006;12:
3115–3123.
26. Sonveaux P, Dessy C, Martinive P, Havaux X, Jordan BF, Gallez B,
Gregoire V, Balligand JL, Feron O. Endothelin-1 is a critical mediator of
myogenic tone in tumor arterioles: implications for cancer treatment.
Cancer Res 2004;64:3209–3214.
27. Ansiaux R, Baudelet C, Jordan BF, Beghein N, Sonveaux P, De Wever J,
Martinive P, Gregoire V, Feron O, Gallez B. Thalidomide radiosensi-
tizes tumors through early changes in the tumor microenvironment.
Clin Cancer Res 2005;11:743–750.
28. Segers J, Fazio VD, Ansiaux R, Martinive P, Feron O, Wallemacq P,
Gallez B. Potentiation of cyclophosphamide chemotherapy using the
anti-angiogenic drug thalidomide: importance of optimal scheduling to
exploit the ’normalization’ window of the tumor vasculature. Cancer
Lett 2006;244:129–135.
29. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy:
a new paradigm for combination therapy. Nat Med 2001;7:987–989.
30. Ansiaux R, Baudelet C, Cron GO, Segers J, Dessy C, Martinive P, De
Wever J, Verrax J, Wauthier V, Beghein N, Gregoire V, Buc Calderon P,
Feron O, Gallez B. Botulinum toxin potentiates cancer radiotherapy
and chemotherapy. Clin Cancer Res 2006;12:1276–1283.
31. Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Daliani DD, Schulman
CC, Nabulsi AA, Humerickhouse RA, Weinberg MA, Schmitt JL, Nel-
son JB. Effect of endothelin-A receptor blockade with atrasentan on
tumor progression in men with hormone-refractory prostate cancer: a
randomized, phase II, placebo-controlled trial. J Clin Oncol 2003;21:
679–689.
32. Michaelson MD, Kaufman DS, Kantoff P, Oh WK, Smith MR. Random-
ized phase II study on Atrensentan alone or in combination with
zoledronic acid in men with metastatic prostate cancer. Cancer 2006;
107:530–535.
33. Figg WD, Li H, Sissung T, Retter A, Wu S, Gulley JL, Arlen P, Wright JJ,
Parnes H, Fedenko K, Latham L, Steinberg SM, Jones E, Chen C, Dahut
W. Pre-clinical and clinical evaluation of estramustine, docetaxel and
thalidomide combination in androgen-independent prostate cancer.
Br J Urol 2007;99:1047–1055.
34. Klein AW. Complications, adverse reactions, and insights with the use
of botulinum toxin. Dermatol Surg 2003;29:549–556
35. Taper HS, Woolley GW, Teller MN, Lardis MP. A new transplantable
mouse liver tumor of spontaneous origin. Cancer Res 1966;26:143–148.
36. Fields MT, Eisbruch A, Normolle D, Orfali A, Davis MA, Pu AT,
Lawrence TS. Radiosensitization produced in vivo by once- vs. twice-
weekly 22-diﬂuoro-2-deoxycytidine (gemcitabine). Int J Radiat Oncol
Biol Phys 2000;47:785–791.
37. Gudbjartsson H, Patz S. The rician distribution of noisy MRI data. Magn
Reson Med 1995;34:910–914.
38. Hayes C, Padhani AR, Leach MO. Assessing changes in tumour vascu-
lar function using dynamic contrast-enhanced magnetic resonance im-
aging. NMR Biomed 2002;15:154–163.
19F NMR In Vivo Reﬂects Gemcitabine Enhancement 27
